1. Gubatan J, Keyashian K, Rubin SJS, et al. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol. 2021;14:333–42.
2. Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts. Inflamm Bowel Dis. 2019;25(2):270–82.
3. EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd. CAROGRA® tablets, approved in Japan for treatment of ulcerative colitis: the world-first orally available α4 integrin antagonist [media release]. https://www.eapharma.co.jp/en/news/2022/0328_2.html. Accessed 28 Mar 2022
4. EA Pharma Co., Ltd. Carogra (carotegrast methyl): Japanese prescribing information. 2022. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/111890_23990A7F1020_1_02. Accessed 14 Apr 2022.
5. Ajinomoto Pharmaceuticals Co., Ltd., Kissei Pharmaceutical Co., Ltd. Kissei and Ajinomoto Pharmaceuticals announce partnership for joint development and marketing of AJM300 and AJG511 for treatment of ulcerative colitis in Japan [media release]. https://www.eapharma.co.jp/en/news/2015/0331.html. Accessed 31 Mar 2015